+++
title = "Patient-Controlled Analgesia"
date = 2024-03-01T00:00:00-05:00
lastmod = 2026-01-15T00:00:00-05:00
content_type = "policies"
audience = "clinician"
category = ["Pain Management", "Medication Safety", "Infusion Therapy"]
tags = ["patient-controlled analgesia", "PCA", "opioids", "OIRD", "respiratory depression", "AACA", "pain assessment", "smart pump", "authorized agent-controlled analgesia"]
author = ["Dennis Woo", "Dr. Mike Stern", "I.M. Wright"]
description = "Clinical practice guideline establishing standards for safe and effective implementation of patient-controlled analgesia across healthcare settings, including pharmacologic agents, routes of administration, monitoring requirements, and authorized agent-controlled analgesia protocols."
slug = "patient-controlled-analgesia"
keywords = ["patient-controlled analgesia", "PCA", "opioid analgesia", "OIRD respiratory depression", "PCA safety", "authorized agent controlled analgesia", "AACA", "epidural analgesia", "multimodal pain management"]
authority = "Vascular Access Governance Committee"
effective_date = "2024-03-01"
+++

# Patient-Controlled Analgesia

## **1. Introduction and Scope**

Patient-controlled analgesia (PCA) represents a cornerstone of modern pain management, empowering patients to self-administer analgesic medications within prescribed safety parameters. This guideline establishes clinical standards for the safe and effective implementation of PCA therapy across healthcare settings, including acute care, ambulatory, and home-based environments.

The primary objective of PCA therapy is to achieve adequate pain control while minimizing medication-related adverse effects. When implemented appropriately, PCA offers several documented advantages over traditional intermittent analgesic administration, including enhanced patient autonomy, reduced delays in pain treatment, decreased incidence of breakthrough pain, improved functional mobility, and more efficient utilization of nursing resources (Faerber et al., 2017; Peng et al., 2018; Wirz et al., 2021).

---

## **2. Foundational Competencies**

### **2.1 Required Clinical Knowledge**

Clinicians responsible for PCA administration must demonstrate comprehensive understanding of the pharmacological agents used in PCA therapy. This knowledge base encompasses pharmacokinetic and pharmacodynamic principles, equianalgesic dosing calculations, contraindications, adverse effect profiles and their management, appropriate delivery modalities, and expected therapeutic outcomes.

### **2.2 Collaborative Decision-Making**

The decision to initiate PCA therapy should emerge from collaborative discussion among the patient, caregivers when appropriate, and the interdisciplinary healthcare team. This assessment must evaluate PCA-specific risk factors alongside the patient's cognitive capacity to comprehend and participate effectively in the therapy. Pain management planning should remain comprehensive, individualized, and goal-oriented, with clearly defined, measurable objectives developed in partnership with the patient and caregivers.

---

## **3. Pharmacological Agents**

### **3.1 Commonly Utilized Medications**

Opioids constitute the most frequently administered medication class for PCA delivery. Agents with established efficacy in PCA applications include morphine, fentanyl, hydromorphone, oxycodone, sufentanil, and remifentanil (Gao et al., 2018; Sujka et al., 2020; Peng et al., 2018). Additional medications and combination regimens have demonstrated utility in specific clinical contexts, including dexmedetomidine, dezocine, ketamine, and tramadol combined with lornoxicam (Li et al., 2021; Jin et al., 2019; Han et al., 2022).

### **3.2 Meperidine Considerations**

Systematic review evidence examining meperidine use in postoperative and obstetric patient populations has identified an unfavorable risk-benefit profile compared to alternative opioids. Meperidine demonstrates elevated adverse effect rates and diminished analgesic efficacy, rendering it unsuitable for PCA therapy in most clinical circumstances (Wong & Cheung, 2020).

### **3.3 Drug Stability Requirements**

All medications prepared for PCA delivery must have established chemical and physical stability data supporting their use in the intended delivery system and duration of administration (Kondasinghe et al., 2021; Daouphars et al., 2018; Chen et al., 2018).

---

## **4. Routes of Administration**

### **4.1 Intravenous and Subcutaneous PCA**

Intravenous and subcutaneous PCA have demonstrated safety and efficacy across diverse patient populations and care settings. Evidence supports their application in palliative care, cancer-related pain management, vaso-occlusive crises, and postoperative analgesia in both pediatric and adult patients when appropriate safety measures are implemented (Rajapakse et al., 2019; Nijland et al., 2019; Grossoehme et al., 2022).

The pharmacokinetic and pharmacodynamic parameters for PCA therapy in neonatal and pediatric populations require additional research to optimize dosing strategies and safety protocols (Nijland et al., 2019; Grossoehme et al., 2022; Muirhead et al., 2022).

### **4.2 Epidural Patient-Controlled Analgesia**

Epidural analgesia maintains its position as the gold standard for postoperative pain management following numerous abdominal, thoracic, and orthopedic surgical procedures. This approach consistently yields lower pain scores, improved mobility, and favorable long-term outcomes compared to systemic alternatives. However, epidural catheter placement carries inherent contraindications—including anticoagulation therapy, active infection, patient refusal, and anatomic variants—and procedural risks such as hypotension, neurovascular injury, and infectious complications.

When epidural administration is contraindicated or otherwise unavailable, intravenous PCA serves as an effective alternative across multiple clinical settings (Tseng et al., 2019; Chen et al., 2019; Falk et al., 2021; Kikuchi et al., 2019; Jung et al., 2017; Cho et al., 2017; Babazade et al., 2019).

### **4.3 Obstetric Applications**

In labor and delivery settings, epidural analgesia remains the predominant modality for managing labor pain, employing various delivery modes including continuous infusion, programmed intermittent bolus, and patient-controlled epidural analgesia (Roofthooft et al., 2020; Khaneshi et al., 2020). However, epidural-associated complications—notably maternal hypotension and fever—have prompted investigation of alternative approaches.

Remifentanil PCA has emerged as a viable alternative to epidural analgesia during labor. As a potent, ultra-short-acting opioid, remifentanil offers rapid onset and offset characteristics advantageous for labor analgesia. However, its use necessitates continuous monitoring given elevated risks of maternal hypoxemia, bradycardia, and hypotension, with careful attention to both maternal and neonatal outcomes (Zhang et al., 2021; Lu et al., 2020; Leong et al., 2021).

---

## **5. Risk Assessment and Adverse Effects**

### **5.1 Opioid-Related Complications**

Opioid-based PCA therapy carries a well-characterized spectrum of potential complications. Clinicians must maintain vigilance for opioid-induced hyperalgesia, cardiovascular effects (hypotension, bradycardia), respiratory depression, gastrointestinal disturbances (nausea, vomiting, constipation, ileus), pruritus, urinary retention, pressure ulcer development, tolerance, and physiological dependence (Li et al., 2021; Muirhead et al., 2022; Falk et al., 2021; Sarwahi et al., 2021; Hines & Owings, 2021; Zha et al., 2019; Yang et al., 2022).

Pediatric patients face additional risk for iatrogenic withdrawal syndrome, a constellation of tolerance and dependence symptoms requiring specialized monitoring and management protocols (Muirhead et al., 2022). These complications collectively contribute to extended hospitalizations, increased morbidity, and in severe cases, mortality.

### **5.2 Opioid-Induced Respiratory Depression**

Opioid-induced respiratory depression (OIRD) represents the most serious potential complication of PCA therapy. The pathophysiology involves a triad of decreased respiratory drive, diminished level of consciousness, and upper airway obstruction. OIRD has been associated with prolonged hospital stays, increased readmission rates, and mortality (Steele et al., 2020; AORN, 2021).

Established risk factors for OIRD include prematurity, advanced age, male sex, morbid obesity, known or suspected sleep-disordered breathing, pre-existing pulmonary or cardiac disease, renal insufficiency, hepatic impairment, and the use of continuous basal infusion rates (Grissinger, 2019; Steele et al., 2020; AORN, 2021; Khanna et al., 2020; Stites et al., 2021).

---

## **6. Alternative and Adjunctive Strategies**

### **6.1 Modified PCA Delivery Modes**

Research has explored alternative PCA delivery paradigms designed to reduce opioid consumption or eliminate PCA-associated risks. Investigated approaches include oral patient-controlled analgesia, time-scheduled decremental continuous infusion, variable-rate feedback infusion with demand dosing, and adaptive algorithms that modify delivery based on patient demand patterns and physiological parameters (Wirz et al., 2021; Leong et al., 2021; Zhu et al., 2019; Lee et al., 2019).

### **6.2 Multimodal Analgesia**

Multimodal pain management strategies have demonstrated particular value for high-acuity surgical patients, including those undergoing total joint arthroplasty, spinal fusion, and major abdominal or thoracic procedures. Effective multimodal approaches incorporate enhanced recovery after surgery (ERAS) protocols, local anesthetic infiltration (wound or intra-articular), epidural or intrathecal adjuncts, regional nerve blocks (such as intercostal blockade), and non-opioid analgesic agents (Jin et al., 2020; Chen et al., 2019; Beloeil et al., 2019; Wang et al., 2022; Ma et al., 2022; Yu et al., 2018; Singh et al., 2017).

### **6.3 Synergistic Medication Combinations**

Certain medication combinations exhibit synergistic effects with opioids while potentially mitigating opioid-related adverse effects. Dexmedetomidine, ropivacaine, ketamine, and low-dose or ultra-low-dose naloxone have each demonstrated favorable outcomes in combination with opioid PCA. Ultra-low-dose naloxone appears to enhance opioid antinociceptive effects while reducing postoperative nausea and vomiting (Gao et al., 2018; Jin et al., 2020; Tseng et al., 2019; Boenigk et al., 2019; Hines & Owings, 2021; Firouzian et al., 2018).

---

## **7. Authorized Agent-Controlled Analgesia**

### **7.1 Indications and Patient Selection**

Authorized agent-controlled analgesia (AACA) extends the benefits of patient-controlled dosing to individuals unable to participate directly in PCA therapy. Patient/nurse-controlled analgesia (PNCA) represents a related modality for infants, children, and critically ill adults. These approaches require careful patient selection and robust protocols to maintain safety (Xing et al., 2019; Benjenk et al., 2020; Rajapakse et al., 2019).

### **7.2 Protocol Development**

Institutions implementing AACA must establish predefined protocols or clinical algorithms with explicit assessment parameters governing dose delivery and adjustment. In the absence of structured protocols, PCA by proxy has been associated with adverse patient outcomes (Grissinger, 2019).

### **7.3 Caregiver Education**

Caregivers authorized to administer PCA doses require comprehensive education with documented competency evaluation. Training must address patient assessment techniques, parameters requiring provider notification, pump operation procedures, appropriate actions when therapy fails to meet patient needs, and contact information for support services.

### **7.4 Outpatient Oversight**

Home-based AACA programs require oversight from a healthcare organization capable of ensuring protocol compliance, supply availability, and expertise in managing complications and device-related concerns. Community-based nursing services typically fulfill this supervisory function (Xing et al., 2019; Benjenk et al., 2020; Rajapakse et al., 2019; Nijland et al., 2019; Grossoehme et al., 2022; Muirhead et al., 2022).

---

## **8. Standardization and Safety Protocols**

### **8.1 Medication Standardization**

Healthcare facilities should implement standardized medication concentrations for PCA and AACA therapy. Standardized or preprinted provider order sets facilitate individualization of dosing while reducing medication error risk (Grissinger, 2019; Muirhead et al., 2022; Steele et al., 2020; The Joint Commission, 2017, 2018).

### **8.2 Dosing Principles**

Analgesic dosing decisions must incorporate comprehensive patient assessment rather than relying solely on pain intensity scores, whether numeric or behavioral. Patient-specific factors including age, weight, renal and hepatic function, concurrent medications, and prior opioid exposure inform appropriate dosing (Gao et al., 2018; Nijland et al., 2019; Lawal et al., 2018; Muirhead et al., 2022; Wang et al., 2022; Sarwahi et al., 2021; Hines & Owings, 2021; The Joint Commission, 2017, 2018; Essex et al., 2020).

### **8.3 Independent Double-Check**

Prior to PCA initiation and whenever the syringe, solution container, medication, or rate is changed, two clinicians must independently verify all parameters. PCA administration represents a complex process with multiple potential error points, with the administration phase demonstrating the highest reported error rates. Errors have resulted in treatment delays, intensified pain, cardiopulmonary compromise, and patient death.

Verification must specifically address the medication, concentration, dose, and infusion rate against the provider order and pump programming. Additionally, clinicians must confirm that administration set configuration enables immediate analgesic delivery while preventing retrograde medication flow (Peng et al., 2018; Lawal et al., 2018; Lee et al., 2019).

---

## **9. Monitoring Requirements**

### **9.1 Respiratory Monitoring**

Patients with identified OIRD risk factors require continuous respiratory monitoring utilizing capnography, pulse oximetry, or other clinically validated methods. Continuous capnography provides earlier detection of respiratory depression compared to pulse oximetry alone and is associated with significant reductions in OIRD incidence, opioid treatment duration, and serious opioid-related adverse events (Zhang et al., 2021; Lu et al., 2020; The Joint Commission, 2017, 2018; Essex et al., 2020; Steele et al., 2020; AORN, 2021; Stites et al., 2021; Akcil et al., 2018).

Clinicians must evaluate the accuracy of the selected capnography device (oral versus nasal) and adjust as needed to optimize monitoring fidelity (Messmer & Ishak, 2017). Supplemental oxygen delivery can mask declining respiratory drive by maintaining oxygen saturation despite hypoventilation; this phenomenon requires careful consideration when interpreting monitoring data (Steele et al., 2020; AORN, 2021; Stites et al., 2021).

### **9.2 Sedation Assessment**

Regular assessment using a validated sedation scale, combined with direct evaluation of cardiopulmonary status quality and adequacy, constitutes essential monitoring for all PCA patients (Gao et al., 2018; Nijland et al., 2019; Wirz et al., 2021; Muirhead et al., 2022; Zhu et al., 2019).

### **9.3 Alarm Management**

Individual alarm parameters should be customized for each patient to ensure alarm validity while minimizing alarm fatigue. Generic alarm settings may fail to detect clinically significant changes in individual patients or may generate excessive false alarms that desensitize clinical staff (Grissinger, 2019; Stites et al., 2021).

### **9.4 Concurrent Sedative Use**

The concomitant administration of sedating medications with opioid therapy requires careful evaluation of cumulative sedation risk. Drug interactions and additive effects can precipitate respiratory compromise even when individual agents are administered at therapeutic doses (Boenigk et al., 2019; Khanna et al., 2020; Stites et al., 2021).

---

## **10. Comprehensive Patient Assessment**

### **10.1 Pain Assessment**

Regular assessment and reassessment of pain using validated, reliable, developmentally appropriate instruments individualized to the patient represents a fundamental component of PCA therapy. Assessment should capture pain at rest and with movement, utilizing patient self-report when possible or objective behavioral measures when self-report is unavailable (Grissinger, 2019; Xing et al., 2019; Benjenk et al., 2020; Rajapakse et al., 2019; Gao et al., 2018; Li et al., 2021; Nijland et al., 2019; Wirz et al., 2021; Muirhead et al., 2022; Tseng et al., 2019; Chen et al., 2019; Wang et al., 2022; Zha et al., 2019; Zhu et al., 2019).

Pain assessment tools validated for palliative care and end-of-life contexts represent an area requiring additional research development. Current assessment instruments are generally optimized for acute pain and may inadequately reflect quality-of-life considerations central to end-of-life care (Rajapakse et al., 2019).

### **10.2 Functional Monitoring**

Beyond pain intensity, monitoring should encompass functional milestones, breakthrough pain episodes, and the patient's ability to participate in therapeutic activities. Patient and caregiver satisfaction with analgesia provides valuable information regarding therapy adequacy (Gao et al., 2018; Sujka et al., 2020; Peng et al., 2018; Lawal et al., 2018; Wirz et al., 2021; Tseng et al., 2019; Roofthooft et al., 2020; Wang et al., 2022; Hines & Owings, 2021; Zhu et al., 2019; Singh et al., 2017).

### **10.3 Adverse Effect Surveillance**

Systematic monitoring for opioid-related adverse effects must include nausea, vomiting, urinary retention, and constipation. Risk factors for opioid-related nausea and vomiting should be assessed and prophylactic or treatment interventions implemented as indicated (Chae et al., 2020).

### **10.4 Device and Access Monitoring**

Regular evaluation of PCA device function—including documentation of injection attempts versus successful deliveries—and assessment for potential patient or caregiver manipulation ensures therapy integrity (Lawal et al., 2018; Lee et al., 2019). Vascular access device assessment encompasses site inspection and patency confirmation to ensure reliable analgesic delivery.

---

## **11. Patient and Caregiver Education**

Educational content for patients and caregivers should be tailored to the anticipated therapy duration and care setting. Core educational elements include treatment options, PCA therapy purpose and operation, monitoring frequency, expected outcomes, necessary precautions, potential adverse effects, symptoms warranting immediate reporting, and the process for dose adjustment (Nijland et al., 2019; Khaneshi et al., 2020; Sarwahi et al., 2021; The Joint Commission, 2017, 2018; Lee et al., 2019).

---

## **12. Treatment Modification**

The pain management plan requires ongoing evaluation with modification as clinically indicated. Adjustments should reflect current pain control status and the presence or absence of adverse effects. When PCA therapy fails to achieve therapeutic goals or produces unacceptable adverse effects, transition to alternative analgesic modalities should be considered (Rajapakse et al., 2019; Leong et al., 2021; Lee, 2020; The Joint Commission, 2017, 2018).

---

## **13. Clinician Education**

Healthcare professionals involved in PCA therapy require education addressing pain assessment principles, opioid pharmacokinetics and pharmacodynamics, adjuvant medication properties, risks associated with concurrent sedative administration, electronic infusion pump operation, and individualized pain management approaches (Grissinger, 2019; Chen et al., 2018; Lawal et al., 2018; Boenigk et al., 2019; The Joint Commission, 2017, 2018; Lee et al., 2019; Campoe & Giuliano, 2017).

---

## **14. Care Transitions**

Adequate pain management and patient stability must be confirmed during handoffs between clinicians and during transitions across care settings. Communication protocols should ensure continuity of PCA parameters, monitoring requirements, and the current status of pain control and adverse effects (Grissinger, 2019; AORN, 2021).

---

## **15. Quality and Safety Processes**

### **15.1 Equipment Selection**

Clinician participation in the selection and evaluation of PCA infusion pumps and monitoring equipment ensures that device capabilities align with clinical requirements. Evaluation criteria should address programmable safety limits, interface usability, alarm functionality, and integration with institutional systems (Suess et al., 2024).

### **15.2 Quality Improvement Activities**

Ongoing quality processes supporting PCA safety include review of opioid reversal administration and opioid-related resuscitation events, evaluation of clinical decision support technology, workflow assessment, barcode medication verification analysis, root cause analysis of adverse events, Healthcare Failure Mode and Effect Analysis, evaluation of long-term outcomes from pain management strategies, and participation in prescription drug monitoring programs to track opioid utilization patterns (Jin et al., 2020; Jin et al., 2019; Muirhead et al., 2022; Ma et al., 2022; The Joint Commission, 2017, 2018; Lee et al., 2019; Campoe & Giuliano, 2017).

---

## **References**

Akcil, E. F., Dilmen, O. K., Vehid, H. E., Yentur, E., & Tunali, Y. (2018). The role of "integrated pulmonary index" monitoring during morphine-based intravenous patient-controlled analgesia administration following supratentorial craniotomies: A prospective, randomized, double-blind controlled study. *Current Medical Research and Opinion, 34*(11), 2009–2014.

AORN. (2021). Fatal patient-controlled analgesia (PCA) opioid-induced respiratory depression. *AORN Journal, 114*(1), 108–110.

Babazade, R., Saasouh, W., Naylor, A. J., et al. (2019). The cost-effectiveness of epidural, patient-controlled intravenous opioid analgesia, or transversus abdominis plane infiltration with liposomal bupivacaine for postoperative pain management. *Journal of Clinical Anesthesia, 53*, 56–63.

Beloeil, H., Albaladejo, P., Sion, A., et al. (2019). Multicentre, prospective, double-blind, randomised controlled clinical trial comparing different non-opioid analgesic combinations with morphine for postoperative analgesia: The OCTOPUS study. *British Journal of Anaesthesia, 122*(6), e98–e106.

Benjenk, I., Messing, J., Lenihan, M. J., et al. (2020). Authorized agent–controlled analgesia for pain management in critically ill adult patients. *Critical Care Nursing, 40*(3), 31–36.

Boenigk, K., Echevarria, G. C., Nisimov, E., et al. (2019). Low-dose ketamine infusion reduces postoperative hydromorphone requirements in opioid-tolerant patients following spinal fusion: A randomised controlled trial. *European Journal of Anaesthesiology, 36*(1), 8–15.

Campoe, K. R., & Giuliano, K. K. (2017). Impact of frequent interruption on nurses' patient-controlled analgesia programming performance. *Human Factors, 59*(8), 1204–1213.

Chae, D., Kim, S. Y., Song, Y., et al. (2020). Dynamic predictive model for postoperative nausea and vomiting for intravenous fentanyl patient-controlled analgesia. *Anaesthesia, 75*(2), 218–226.

Chen, L., Wu, Y., Cai, Y., et al. (2019). Comparison of programmed intermittent bolus infusion and continuous infusion for postoperative patient-controlled analgesia with thoracic paravertebral block catheter: A randomized, double-blind, controlled trial. *Regional Anesthesia and Pain Medicine, 44*(2), 240–245.

Chen, P., Chen, F., Zhou, B. H., & Aslam, M. S. (2018). Compatibility and stability of dezocine and tropisetron in 0.9% sodium chloride injection for patient-controlled analgesia administration. *Medicine, 97*(50), e13698.

Cho, J., Kim, H. I., Lee, K. Y., et al. (2017). Comparison of the effects of patient-controlled epidural and intravenous analgesia on postoperative bowel function after laparoscopic gastrectomy: A prospective randomized study. *Surgical Endoscopy, 31*(11), 4688–4696.

Daouphars, M., Hervouët, C. H., Bohn, P., et al. (2018). Physicochemical stability of oxycodone-ketamine solutions in polypropylene syringe and polyvinyl chloride bag for patient-controlled analgesia use. *European Journal of Hospital Pharmacy, 25*(4), 214–217.

Essex, M. N., Camu, F., Borgeat, A., Salomon, P. A., Pan, S., & Cheung, R. (2020). The relationship between postoperative opioid consumption and the incidence of hypoxemic events following total hip arthroplasty: A post hoc analysis. *Canadian Journal of Surgery, 63*(3), e250–e253.

Faerber, J., Zhong, W., Dai, D., et al. (2017). Comparative safety of morphine delivered via intravenous route vs. patient-controlled analgesia device for pediatric inpatients. *Journal of Pain and Symptom Management, 53*(5), 842–850.

Falk, W., Magnuson, A., Eintrei, C., et al. (2021). Comparison between epidural and intravenous analgesia effects on disease-free survival after colorectal cancer surgery: A randomised multicentre controlled trial. *British Journal of Anaesthesia, 127*(1), 65–74.

Firouzian, A., Gholipour Baradari, A., Alipour, A., et al. (2018). Ultra-low-dose naloxone as an adjuvant to patient controlled analgesia (PCA) with morphine for postoperative pain relief following lumber discectomy: A double-blind, randomized, placebo-controlled trial. *Journal of Neurosurgical Anesthesiology, 30*(1), 26–31.

Gao, Y., Xiaoming, D., Hongbing, Y., et al. (2018). Patient-controlled intravenous analgesia with combination of dexmedetomidine and sufentanil on patients after abdominal operation: A prospective, randomized, controlled, blinded, multicenter clinical study. *The Clinical Journal of Pain, 34*(2), 155–161.

Grissinger, M. (2019). Worth repeating: PCA by proxy event suggests reassessment of practices that may have fallen by the wayside. *Pharmacy and Therapeutics, 44*(10), 580–581.

Grossoehme, D. H., Brown, M., Richner, G., Zhou, S. M., & Friebert, S. (2022). A retrospective examination of home PCA use and parental satisfaction with pediatric palliative care patients. *American Journal of Hospice and Palliative Medicine, 39*(3), 295–307.

Han, Y., Li, P., Miao, M., Tao, Y., Kang, X., & Zhang, J. (2022). S-Ketamine as an adjuvant in patient-controlled intravenous analgesia for preventing postpartum depression: A randomized controlled trial. *BMC Anesthesiology, 22*(1), 1–7.

Hines, C. B., & Owings, C. R. (2021). Opioids: Understanding how acute actions impact chronic consequences. *Dimensions of Critical Care Nursing, 40*(5), 268–274.

Jin, J., Min, S., Chen, Q., Zhang, D., & Gharaei, H. (2019). Patient-controlled intravenous analgesia with tramadol and lornoxicam after thoracotomy: A comparison with patient-controlled epidural analgesia. *Medicine, 98*(7), e14538.

Jin, X., & Wu, Y. (2020). Study on main drugs and drug combinations of patient-controlled analgesia based on text mining. *Pain Research and Management*, 8517652.

Jung, J. H., Kim, G. S., Lee, J. J., et al. (2017). Comparison of intrathecal morphine and surgical-site infusion of ropivacaine as adjuncts to intravenous patient-controlled analgesia in living-donor kidney transplant recipients. *Singapore Medical Journal, 58*(11), 666–673.

Khanna, A. K., Bergese, S. D., Jungquist, C. R., et al. (2020). Prediction of opioid-induced respiratory depression on inpatient wards using continuous capnography and oximetry: An international prospective, observational trial. *Anesthesia and Analgesia, 131*(4), 1012–1024.

Khaneshi, R., Rasooli, S., Moslemi, F., & Fakour, S. (2020). Comparison of continuous epidural infusion of bupivacaine and fentanyl versus patient controlled analgesia techniques for labor analgesia: A randomized controlled trial (RCT). *Journal of Reproduction and Infertility, 21*(1), 42–48.

Kikuchi, S., Kuroda, S., Nishizaki, M., et al. (2019). Comparison of the effects of epidural analgesia and patient-controlled intravenous analgesia on postoperative pain relief and recovery after laparoscopic gastrectomy for gastric cancer. *Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 29*(5), 405–408.

Kondasinghe, J. S., Tuffin, P. H. R., & Findlay, F. J. (2021). Subcutaneous patient-controlled analgesia in palliative care. *Journal of Pain and Palliative Care Pharmacotherapy, 35*(3), 163–166.

Lawal, O. D., Mohanty, M., Elder, H., et al. (2018). The nature, magnitude, and reporting compliance of device-related events for intravenous patient-controlled analgesia in the FDA manufacturer and user facility device experience (MAUDE) database. *Expert Opinion on Drug Safety, 17*(4), 347–357.

Lee, S. H., Baek, C. W., Kang, H., et al. (2019). A comparison of 2 intravenous patient-controlled analgesia modes after spinal fusion surgery: Constant-rate background infusion versus variable-rate feedback infusion, a randomized controlled trial. *Medicine, 98*(10), e14753.

Lee, Y., & Kim, K. (2020). Factors related to the consumption of patient-controlled postoperative analgesics in Korea: A retrospective study. *Pain Management Nursing, 21*(5), 449–455.

Lee, Y., Kim, K., & Kim, M. (2019). Errors in postoperative administration of intravenous patient-controlled analgesia: A retrospective study. *American Journal of Nursing, 119*(4), 22–27.

Leong, W. L., Sultana, R., Han, N. L. R., Sia, A. T. H., & Sng, B. L. (2021). Evaluation of vital signs-controlled, patient-assisted intravenous analgesia (VPIA) using remifentanil for labor pain. *Journal of Clinical Anesthesia, 75*, 110480.

Li, Q., Yao, H., Xu, M., & Wu, J. (2021). Dexmedetomidine combined with sufentanil and dezocine-based patient-controlled intravenous analgesia increases female patients' global satisfaction degree after thoracoscopic surgery. *Journal of Cardiothoracic Surgery, 16*(1), 1–7.

Lu, G., Yao, W., Chen, X., Zhang, S., & Zhou, M. (2020). Remifentanil patient-controlled versus epidural analgesia on intrapartum maternal fever: A systematic review and meta-analysis. *BMC Pregnancy and Childbirth, 20*(1), 1–9.

Ma, B., Sun, Y., Hao, C., Liu, X., & Shen, S. (2022). Patient-controlled intravenous analgesia with or without ultrasound-guided bilateral intercostal nerve blocks in children undergoing the Nuss procedure: A randomized, double-blinded, controlled trial. *Pain Research and Management*, 5776833.

Messmer, A., & Ishak, D. (2017). Nasal capnography during remifentanil patient-controlled analgesia in labour. *International Journal of Obstetric Anesthesia, 32*, 91–92.

Muirhead, R., Kynoch, K., Peacock, A., & Lewis, P. A. (2022). Safety and effectiveness of parent- or nurse-controlled analgesia in neonates: A systematic review. *JBI Evidence Synthesis, 20*(1), 3–36.

Nijland, L., Schmidt, P., Frosch, M., et al. (2019). Subcutaneous or intravenous opioid administration by patient-controlled analgesia in cancer pain: A systematic literature review. *Supportive Care in Cancer, 27*(1), 33–42.

Peng, Z., Zhang, Y., Guo, J., Guo, X., & Feng, Z. (2018). Patient-controlled intravenous analgesia for advanced cancer patients with pain: A retrospective series study. *Pain Research and Management*, 7323581.

Rajapakse, D., Kelly, P., Boggs, T., Bluebond-Langner, M., & Henderson, E. M. (2019). Patient-controlled analgesia for children with life-limiting conditions in the community: Results of a prospective observational study. *Journal of Pain and Symptom Management, 57*(5), e1–e4.

Roofthooft, E., Barbé, A., Schildermans, J., et al. (2020). Programmed intermittent epidural bolus vs. patient-controlled epidural analgesia for maintenance of labour analgesia: A two-centre, double-blind, randomised study. *Anaesthesia, 75*(12), 1635–1642.

Sarwahi, V., Hasan, S., Liao, B., et al. (2021). Zero patient-controlled analgesia is an achievable target for postoperative rapid recovery management of adolescent idiopathic scoliosis patients. *Spine, 46*(21), 1448–1454.

Singh, K., Bohl, D. D., An, J., et al. (2017). Multimodal analgesia versus intravenous patient-controlled analgesia for minimally invasive transforaminal lumbar interbody fusion procedures. *Spine, 42*(15), 1145–1150.

Steele, T., Eidem, L., & Bond, J. (2020). Impact of adoption of smart pump system with continuous capnography monitoring on opioid-related adverse event rates: Experience from a tertiary care hospital. *Journal of Patient Safety, 16*(3), e194–e198.

Suess, T. M., Burdick, W. P., Whitman, G. R., et al. (2024). Improving medication safety through smart pump interoperability with the electronic health record in the intensive care unit. *Journal of Patient Safety, 20*(3), 205–208. doi:[10.1097/PTS.0000000000001196](https://doi.org/10.1097/PTS.0000000000001196)

Stites, M., Surprise, J., McNiel, J., Northrop, D., & De Ruyter, M. (2021). Continuous capnography reduces the incidence of opioid-induced respiratory rescue by hospital rapid resuscitation team. *Journal of Patient Safety, 17*(6), e557–e561.

Sujka, J. A., Dekonenko, C., Millspaugh, D. L., et al. (2020). Epidural versus PCA pain management after pectus excavatum repair: A multi-institutional prospective randomized trial. *European Journal of Pediatric Surgery, 30*(5), 465–471.

The Joint Commission. (2017). Pain assessment and management standards for hospitals. https://www.jointcommission.org/standards/r3-report/r3-report-issue-11-pain-assessment-and-management-standards-for-hospitals/

The Joint Commission. (2018a). Pain assessment and management standards for home health services. https://www.jointcommission.org/-/media/tjc/documents/standards/r3-reports/r3_22_pain_standards_hc_12_21_18_final.pdf

The Joint Commission. (2018b). Pain assessment and management standards for nursing care centers. https://www.jointcommission.org/-/media/tjc/documents/standards/r3-reports/r3_21_pain_standards_ncc_12_21_18_final.pdf

Tseng, W. C., Lin, W. L., Lai, H. C., et al. (2019). Fentanyl-based intravenous patient-controlled analgesia with low dose of ketamine is not inferior to thoracic epidural analgesia for acute post-thoracotomy pain following video-assisted thoracic surgery: A randomized controlled study. *Medicine, 98*(28), e16403.

Wang, S., Zhang, T., Wang, P., et al. (2022). The impact of perioperative multimodal pain management on postoperative outcomes in patients (aged 75 and older) undergoing short-segment lumbar fusion surgery. *Pain Research and Management*, 9052246.

Wirz, S., Seidensticker, S., & Shtrichman, R. (2021). Patient-controlled analgesia (PCA): Intravenous administration (IV-PCA) versus oral administration (Oral-PCA) by using a novel device (PCOA® acute) for hospitalized patients with acute postoperative pain—A comparative retrospective study. *Pain Research and Management*, 2542010.

Wong, S. S. C., & Cheung, C. W. (2020). Analgesic efficacy and adverse effects of meperidine in managing postoperative or labor pain: A narrative review of randomized controlled trials. *Pain Physician, 23*(2), 175–201.

Xing, F., An, L. X., Xue, F. S., Zhao, C. M., & Bai, Y. F. (2019). Postoperative analgesia for pediatric craniotomy patients: A randomized controlled trial. *BMC Anesthesiology, 19*(1), 53.

Yang, H., Gu, X., Xu, M., et al. (2022). Preventing nausea and vomiting after gynecological laparoscopic surgery by patient-controlled intravenous analgesia with a naloxone admixture: A randomized controlled trial. *Medicine, 101*(29), e29584.

Yu, S., Dundon, J., Solovyova, O., Bosco, J., & Iorio, R. (2018). Can multimodal pain management in TKA eliminate patient-controlled analgesia and femoral nerve blocks? *Clinical Orthopaedics and Related Research, 476*(1), 101–109.

Zha, M. L., Yu, B. F., Chen, J. Y., Sun, Y. P., & Chen, H. L. (2019). Patient-controlled analgesia and postoperative pressure ulcer: A meta-analysis of observational studies. *Wounds, 31*(1), 1–6.

Zhang, P., Yu, Z., Zhai, M., Cui, J., & Wang, J. (2021). Effect and safety of remifentanil patient-controlled analgesia compared with epidural analgesia in labor: An updated meta-analysis of randomized controlled trials. *Gynecologic and Obstetric Investigation, 86*(3), 231–238.

Zhu, Y., Xie, K., Yuan, J., et al. (2019). Efficacy of oxycodone in intravenous patient-controlled analgesia with different infusion modes after laparoscopic radical surgery of cervical cancer: A prospective, randomized, double-blind study. *Medicine, 98*(34), e16810.
